Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...
In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.
As influencer Hannah Campbell mourns the death of her 10-month-old daughter, Elliana Rose, she is also doing her part to fight the disease that affected her baby girl. “Our sweet girl Elliana Rose ...
Steven Daniel Daveluy, MD, FAAD, discussed how artificial intelligence (AI) can leverage extensive patient data and guide dermatologists to improve early diagnosis and treatment of rare dermatological ...
KaDee Troop is the mother of seven adopted children, four of whom have a rare genetic disorder that causes their skin to blister and tear at the slightest touch. Wounds heal slowly — if at all — and ...
Palvella’s recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious, rare skin diseases that currently have no FDA-approved therapies Top-line ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback